Ann: Kazia launches new SAB, page-2

Board of Directors
Mr Iain RossChairman,Non-Executive Director
Mr Bryce CarmineNon-Executive Director
Mr Steven CoffeyNon-Executive Director
Dr James GarnerChief Executive Officer, Managing Director
Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000
ASX RELEASE
12July2022
KAZIALAUNCHESNEWSCIENTIFIC ADVISORY BOARD COMPRISED OF
WORLD-LEADING EXPERTS IN BRAIN CANCER
Sydney,11 July 2022–Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-
focused drug development company, is pleased toannounce the launch of its Scientific
Advisory Board(SAB). The new SAB consists of fourdistinguishedclinicians and scientists
with expertisein the development ofinnovative therapiesfor brain cancer.
Key Points
•SAB will adviseand guideKazia as paxalisib moves towards anticipated completion of
GBM AGILE in2H CY2023 and potential commercialization thereafter.
•SAB members aresenior experts in the field of brain cancer, with an extensive track
record ofresearch and publication.The initial membership comprises:
oDrPriscilla Brastianos [Massachusetts General Hospital]
oDrJohn de Groot [University of California,San Francisco]
oDr Alan Olivero [independent consultant andinventor of paxalisib]
oDrPatrick Wen [Dana-Farber Cancer Institute]